scholarly journals Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease

2017 ◽  
Vol 65 (3) ◽  
pp. 720-725 ◽  
Author(s):  
Kan Zen ◽  
Mitsuyoshi Takahara ◽  
Osamu Iida ◽  
Yoshimitsu Soga ◽  
Daizo Kawasaki ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Artery Disease

scholarly journals Peripheral stent technology and current status for endovascular treatment of femoropopliteal artery disease: a clinical review

2018 ◽  
Vol 6 (5) ◽  
pp. 1474
Author(s):  
Bhargav Dave ◽  
Rikin Shah
Keyword(s):  
Peripheral Artery Disease ◽  
Current Status ◽  
Stent Fracture ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Nitinol Stents ◽  
Long Term Follow Up ◽  
Drug Eluting ◽  
Artery Disease ◽  
In Stent Restenosis

Over the past decade, the treatment of peripheral artery disease poses a number of technical challenges for the physician. The primary rationale of this article is to review the available literature on the current practices involved in the treatment of peripheral artery disease (PAD), particularly the femoropopliteal lesions. It is evident from the landmark clinical trials that the use of self-expanding drug-eluting stents (DES) has become the most favored clinical strategy for treating peripheral lesions above the knee. It is chiefly due to higher patency rates, and minimal in-stent restenosis and stent fracture rates associated with the use of DES. The technical evolution in the endovascular approach from the use of bare nitinol stents to DES for treating PAD and the factors responsible for this transformation have also been reviewed with their respective justification. Presently there is a need of DES technology for the treatment of femoropopliteal lesions, which can reduce the risk of stent fracture and in-stent restenosis for longer lesions while maintaining patency during long-term follow-up. To conclude, this review establishes that self-expanding DES and drug coated balloons using anti-proliferative drugs like sirolimus and paclitaxel are currently the most effective method of treating the femoropopliteal lesions in PAD.

Drug-Coated Balloons Applications in Interventional Cardiology

2018 ◽  
Vol 24 (4) ◽  
pp. 397-401
Author(s):  
Gianluca Rigatelli ◽  
Marco Zuin
Keyword(s):  
Interventional Cardiology ◽  
Vessel Diameter ◽  
Peripheral Artery ◽  
Small Vessels ◽  
Below The Knee ◽  
Stent Restenosis ◽  
Normal Vessel ◽  
Drug Eluting ◽  
Artery Disease ◽  
And Function

Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function. Methods: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed. Results: As demonstrated by different studies, DCBs have different theoretical advantages over Drug Eluting Stents (DESs), especially for the treatment of some endovascular lesions, as In-Stent Restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites. Conclusion: Despite the need of further studies are needed to elucidate the optimal use of DCBs their current use in interventional cardiology appears promising.

Drug-Eluting Stents for Treatment of Peripheral Artery Disease

2018 ◽  
Vol 18 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Kazeen Abdullah ◽  
Bassel Bou Dargham ◽  
Micah Steinbrecher ◽  
Bo Sun ◽  
Zhao Huiqiang ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Drug Eluting Stents ◽  
Peripheral Artery ◽  
Drug Eluting ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document